½ðɳjs93252¼¯ÍÅ-¿ÆÑ§¼ÒÌá³öǰÁÐÏÙ°©É¸²éµÄз½·¨
2026-03-08 13:53:53

¿ÆÑ§¼ÒÌá³öǰÁÐÏÙ°©É¸²éµÄÐÂÒªÁì

ÈÕÆÚ£º2021-10-29 À´Àú£º±¾Õ¾ ¹©¸å£ºÏÖ´úҽѧÓë´óÖÚÎÀÉú´¦ ×÷ÕߣºÖÎÀíÔ± ÖÖ±ð£ºÒëÎÄ

½üÆÚ£¬Èðµä¿¨ÂÞÁÖ˹¿¨Ñ§ÔºµÄÑо¿ÍŶӷ¢Ã÷£¬ÓڴʲÕñ³ÉÏñ£¨magnetic resonance imaging, MRI£©²é³­µÄ»ù´¡ÉÏ£¬¶ÔÓÚǰÁÐÏÙ°©ÑôÐÔ³ÂËß¾ÙÐаÐÏò»î¼ì¿ÉÒÔÏÔÖø½µµÍ¹ý·ÖÕï¶ÏÂÊ¡£Ïà¸ÉÑо¿ÓÚ¡¶The New England Journal of Medici½ðɳjs93252¼¯ÍÅ-ne¡··¢±í£¬ÌâΪ£ºMRI-Targeted or Standard Biopsy in ProstateCancer Screening¡£ ½ñ³¯£¬Ç°ÁÐÏÙ°©É¸²éµÄ³ß¶È»î¼ì·½°¸ÊÇÓڲⶨǰÁÐÏÙÌØÒìÐÔ¿¹Ô­£¨prostate specific antigen,PSA£©Éý¸ßµÄ»ù´¡ÉÏ£¬¾ÙÐÐÖ±³¦³¬ÉùÖ¸µ¼µÄǰÁÐÏÙ»î¼ì¡£ÕâÀà·½°¸µÄȱÏÝÊÇÇáÒ×ÔÐÓý·¢Éú¹ý·ÖÕï¶ÏÎÊÌâ¡£Ñо¿Ö°Ô±½«PSA¡Ý3ng/mlµÄ½éÈëÕßËæ»ú·ÖΪÁ½×飬³É¹û·¢Ã÷£¬MRI°ÐÏò»î¼ì×éÁÙ´²ÒâÒå°©Ö¢ÂʸßÔڳ߶Ȼî¼ì×飨21% vs 18%; CI -1~7; P 0.001£©£»ÎÞÁÙ´²ÒâÒå°©Ö¢ÂʵÍÔڳ߶Ȼî¼ì×飨4% vs 12%; CI -11~-5; P 0.001£©¡£ ¸ÃÑо¿³É¹û×¢½â£¬¶ÔÓÚMRIÌáÐÑǰÁÐÏÙÇøÓò²¡±äµÄ»¼Õß²ÉÄɰÐÏò»î¼ì£¬¿ÉÒÔÏ÷¼õû±ØÒªÒªµÄÓд´»î¼ì¼°¹ý·ÖÒ½ÖΣ¬ÓÐÍû³ÉΪ½µµÍǰÁÐÏÙ°©É¸²éµÄÐÂÒªÁì¡£ ×¢£º´ËÑо¿½á¹ûÕª×Ô¡¶The New England Journal of Medicine¡·£¬ÎÄÕÂÄÚÈݲ»´ú±í±¾ÍøÕ¾²»Ñŵ㼰̬¶È¡£ Ô­ÎÄÁ´½Ó£ºhttps://www.nejm.org/doi/full/10.1056/NEJMoa2100852-½ðɳjs93252¼¯ÍÅ-



¸ü¶à²âÊÔÊý¾Ý¾´ÇëÆÚ´ý……